


## IQ4I Research released a new drug pipeline report on "Non-alcoholic steatohepataitis (NASH) Pipeline analysis"

This pipeline analysis gives comprehensive insights on drugs being developed for treatment of NASH & their various stages of development in 144 slide decks.

BOSTON, MASSACHUSETTS, U.S., February 22, 2017 /EINPresswire.com/ --"Non-alcoholic steatohepataitis (NASH) Pipeline Analysis" gives comprehensive insights on the various drugs being developed for the treatment of NASH. The report covers all the drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, antibodies, stem cell therapies, recombinant proteins and



RNA-based therapeutics, but excludes symptom relief drugs, generic combinations and supplemental drugs. The report also covers some of the hot targets in research for NASH treatments and NASH related biomarkers.

This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Nonalcoholic steatohepataitis (NASH) drugs market. The report also provides strategic insights on some of the molecules that are yet to be launched in the next few years. Some of the key sections covered in the report are given below:

• Epidemiology

o In this section, epidemiology of NASH is reviewed to understand potential significance and impact of the disease.

o Global & US prevalence rates

• Hot Targets, Mechanisms & Therapies

o In this section, various NASH associated targets, mechanism and upcoming therapies are discussed. Also, covers novel targets in early research for NASH along with disease progression biomarkers associated with NASH (Inflammatory, apoptosis, fibrosis).

## • Market analysis

o In market analysis section, global NASH drugs market is indicated along with the estimated Peak

sales (\$) of leading clinical stage drugs forecasted from 2019-2025.

o Forecasting model for NASH market.

o NASH market dynamics

o NASH Market and estimated Peak sales of 8 clinical candidates (OCA-Intercept, Aramchol-Galmed, o GR-MD-02-Gilead, Cenicriviroc-Tobira, Simtuzumab-Gilead, Remo Biphasic-Avolynt, IVA 337-Inventiva Pharma, GFT505-Genfit)

o NASH related deals analysis with financials (upfront, milestones and royalties)

o Funding scenario in NASH market

• Pipeline Analysis

o Pipeline analysis was carried to get deeper insights on various treatment modalities in discovery, preclinical & development section, pipelines from major companies were identified and Potential targets were reported along with Mechanism of action, Current development status & nature of molecule. Pipeline analysis by developmental stage (Discovery to Clinical development)

- o Pipeline analysis by modalities
- \_ Monoclonal Antibodies pipeline analysis
- \_ RNA-therapeutics pipeline analysis
- \_ Recombinant protein pipeline analysis
- o Pipeline analysis by leading players & Target analysis

o Drug analysis based on mechanism (Anti-Inflammatory, Anti-fibrotic & Metabolic)

• Key Players Analysis

o The key player's analysis section provides an in-depth understanding of various companies working on Nonalcoholic steatohepatitis (NASH) and their Pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.

o Global key players overview

o Global key players Pipeline data (Discovery, Pre-clinical & Clinical development)

o Global key players deals (Collaborations, Licensing, Service agreements, grants, funds)

Mr. Satish Birudukota IQ4I Research & Consultancy Pvt Ltd., +91-80-60500229 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.